Chinese english Germany Korea


フルオキセチン 化学構造式
Adofen;Fluval;Foxetin;Fluctin;Reneuron;Fluoxeren;FLUOXETINE;fluoxetina;AURORA KA-7692;(+-)-benzenepropanamin
MOL File:

フルオキセチン 物理性質

融点 :
158 °C
沸点 :
395.1±42.0 °C(Predicted)
比重(密度) :
1.159±0.06 g/cm3(Predicted)
CAS データベース:
54910-89-3(CAS DataBase Reference)
Benzenepropanamine, N-methyl-?-[4-(trifluoromethyl)phenoxy]- (54910-89-3)


フルオキセチン 価格

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入

フルオキセチン 化学特性,用途語,生産方法


フルオキセチン (英: Fluoxetine) は、選択的セロトニン再取り込み阻害薬(SSRI)に分類される抗うつ薬の1つである。


抗うつ薬, 選択的セロトニン再取り込み阻害薬


Prozac was discovered by a team of chemists at the pharmaceutical company Eli Lilly. Key researchers involved in the work were Bryan B. Molloy (1939–2004), Klaus K. Schmiegel (1939–), Ray W. Fuller (1935–1996), and David T. Wong (1935–). In the middle of the 20th century, the main group of drugs for treating depression was tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). TCAs are named because of their three-ring chemical structure. Lilly researchers were working with TCAs in the1950s and 1960s. Prozac was developed by Eli Lilly scientists who based their work on the antihistamine diphenylhydramine; diphenylhydramine hydrochloride is marketed under the trade name Benadryl.the Lilly scientists examined diphenylhydramine because research had demonstrated that some antihistamines, including diphenylhydramine, had the ability to inhibit serotonin and serve as antidepressants.Molloy started examining diphenylhydramine-type compounds for their antidepressant properties in 1970. Molloy and his colleagues discovered fluoxetine hydrochloride had potential as an antidepressant in 1972 and it was referred to as Lilly 110140 in thefirst published articles on the compound, which appeared in 1974. Fluoxetine hydrochloride was no more effective than other antidepressant drugs of the time, but it produced much fewer negative side effects because it interacted specifically with the neurotransmitter serotonin but did not interfere with other neurotransmitters. TCAs inhibited the reuptake of other neurotransmitters along with serotonin. Molloy and Schmiegel applied for a patent in 1974 for the synthesis of arloxyphenylpropylamines (U.S. Patent Number 4314081).the patent named a number of compounds in this class of chemicals that could be used as antidepressants. In 1983, Eli Lilly applied to the Food and Drug Administration (FDA) for approval of fluoxetine hydrochloride as a drug used to treat depression. Prozac was first offered to the public in Belgium in 1986 and in the United States in 1988. Eli Lilly initially had a monopoly on fluoxetine hydrochloride as an antidepressant with its Prozac brand. In the mid-1990s, a lawsuit filed against Eli Lilly led to the loss of their exclusive patent rights, allowing generic fluoxetine hydrochloride antidepressants to be marketed starting in 2001.


Fluoxetine in its hydrochloride salt form is marketed as numerous drugs, the most popular ofwhich is Prozac. Prozac is prescribed for depression, obsessive-compulsive disorder, bulimia,agoraphobia, and premenstrual dysphoric disorder (premenstrual syndrome). Prozac andother fluoxetine medications belong to a class of drugs called selective serotonin reuptakeinhibitors (SSRIs). When a nerve signal is sent, a neurotransmitter, such as serotonin, travelsfrom a presynaptic neuron across the synaptic gap to a postsynaptic neuron. Receptors on thepostsynaptic neuron capture the neurotransmitter, resulting in the transmission of the signal.After performing its function, the neurotransmitter is released back to the presynaptic cellin a process called reuptake. SSRIs slow down the return of serotonin to presynaptic neurons,allowing for a higher serotonin concentration on postsynaptic neurons. Because depressionand other psychological disorders are associated with low serotonin levels, Prozac and otherSSRIs help maintain serotonin levels.
Prozac was thefirst SSRI antidepressant to be marketed. Because Prozac produced lesssevere side effects than other antidepressants, it became the drug of choice for treating depressionand was made available to a wider public. Its use exploded in the 1990s, with sales peakingin 2000 when revenues from Prozac reached $2.5 billion. Eli Lilly’s patent on fluoxetinehydrochloride expired in August 2001; its use continued into the 21st century but on a muchsmaller scale as generic fluoxetine hydrochloride products came on the market. Since its introductionin 1986, Prozac was the most prescribed drug for antidepressant until recent yearswhen it was replaced by Zoloft, Paxil, and Lexapro as the top three antidepressants prescribedin the United States, respectively.
Fluoxetine hydrochloride is most recognized as an antidepressant, but it is also used torelieve symptoms of premenstrual dysphoric disorder (PMDD) (premenstrual syndrome).Th ese symptoms include mood swings, tension, bloating, irritability, and breast tenderness. EliLilly began marketing fl uoxetine hydrochloride as Sarafem in 2000 for treating PMDD.




Rivastigmine Metabolite


Fluoxetine (Prozac) is given in the morning because of its potential for being activating and causing insomnia. Food does not affect its systemic bioavailability and may actually lessen the nausea reported by some patients. Fluoxetine is highly bound to serum proteins and may interact with other highly protein bound drugs. It is demethylated in the liver to form an active metabolite, norfluoxetine. Inactive metabolites are excreted by the kidney.Doses must be reduced in patients with liver disease.
The slow elimination of fluoxetine and norfluoxetine lead to special clinical concerns when adjusting doses and discontinuing this medication. Steady state is not reached until 4 to 6 weeks, and similarly, complete elimination takes 4 to 6 weeks after discontinuation of the medication. A 4- to 6-week waiting period should be permitted before starting a medication with potential for an interaction with fluoxetine, such as a monoamine oxidase inhibitor (MAOI). Additionally, fluoxetine is a potent inhibitor of cytochrome P450 2D6 and can significantly elevate levels of drugs metabolized by this route. Thus, coadministration of drugs with a narrow therapeutic index, such as TCAs and type 1C antiarrhythmics, including flecainide and propafenone, are a particular concern.


In fluoxetine (Prozac), protonated in vivo, the protonatedamino group can H-bond to the ether oxygen electrons, whichcan generate the β-arylamino–like group, with the other arylserving as the characteristic “extra” aryl. The S-isomer ismuch more selective for SERT than for NET. The majormetabolite is the N-demethyl compound, which is as potent asthe parent and more selective (SERT versus NET).
Therapy for 2 or more weeks is required for the antidepressanteffect. Somatodendritic 5-HT1A autoreceptor desensitizationwith chronic exposure to high levels of 5-HT isthe accepted explanation for the delayed effect for this andother serotonin reuptake inhibitors.

フルオキセチン 上流と下流の製品情報



フルオキセチン 生産企業

Global( 134)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21792 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22631 55
Hebei Chisure Biotechnology Co., Ltd.
0311 66567340 CHINA 1012 58
career henan chemical co
+86-371-86658258 CHINA 30057 58
Hubei Jusheng Technology Co.,Ltd.
027-59599243 CHINA 28235 58
Chongqing Chemdad Co., Ltd
+86-13650506873 CHINA 35438 58
86-18523575427 CHINA 47484 58
Mainchem Co., Ltd. +86-0592-6210733
+86-0592-6210733 CHINA 32445 55
Shanghai Boyle Chemical Co., Ltd. Mr Qiu:021-50182298(Demestic market) Miss Xu:021-50180596(Abroad market)
+86-21-57758967 China 2214 55


  • 54910-89-3
  • N-methyl-3-[4-(trifluoromethyl)phenoxy]-3-(3-tritiophenyl)propan-1-amine
  • n-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
  • n-methyl-gamma-(4-(trifluoromethyl)phenoxy)-(+-)-benzenepropamin
  • Duloxetine hydrochoride
  • N-Methyl-3-Phenyl-3-[(A-Trifluoro-P-Tolyl)Oxy]Propylamine
  • Fluoxetine (base and/or unspecified salts)
  • Adofen
  • Fluctin
  • Fluoxeren
  • Foxetin
  • Reneuron
  • 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
  • Fluval
  • N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine
  • (+/-)-n-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
  • AURORA KA-7692
  • (+-)-benzenepropanamin
  • (+)or(-)-n-methyl-3-phenyl-3-(alpha,alpha,alpha-trifluoro-p-tolyl)oxy)prop
  • (3S)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propane-1-amine
  • (S)-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]-N-methyl-1-propanamine
  • (S)-N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropan-1-amine
  • (S)-N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine
  • (3R)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propane-1-amine
  • (R)-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]-N-methyl-1-propanamine
  • (R)-N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropan-1-amine
  • (R)-N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine
  • Methyl[(3S)-3-phenyl-3-[4-(trifluoroMethyl)phenoxy]propyl]aMine
  • N-Methyl-3-phenyl-3-(4-(trifluoroMethyl)phenoxy)propan-1-aMine
  • (R)-3-フェニル-3-[4-(トリフルオロメチル)フェノキシ]-N-メチル-1-プロパンアミン
  • (S)-3-フェニル-3-[4-(トリフルオロメチル)フェノキシ]-N-メチル-1-プロパンアミン
  • フルオキセチン
  • メチル[(R)-3-フェニル-3-[4-(トリフルオロメチル)フェノキシ]プロピル]アミン
  • rac-(R*)-N-メチル-γ-[4-(トリフルオロメチル)フェノキシ]ベンゼンプロパンアミン
  • (R)-N-メチル-γ-[4-(トリフルオロメチル)フェノキシ]ベンゼンプロパン-1-アミン
  • (S)-N-メチル-γ-[4-(トリフルオロメチル)フェノキシ]ベンゼンプロパンアミン
  • (±)-フルオキセチン
  • (-)-フルオキセチン
  • (R)-1-フェニル-1-[4-(トリフルオロメチル)フェノキシ]-3-(メチルアミノ)プロパン
  • (S)-フルオキセチン
  • (3S)-N-メチル-3-フェニル-3-[4-(トリフルオロメチル)フェノキシ]プロパン-1-アミン
  • (R)-フルオキセチン
  • (S)-N-メチル-γ-[4-(トリフルオロメチル)フェノキシ]ベンゼンプロパン-1-アミン
  • (γR)-γ-[4-(トリフルオロメチル)フェノキシ]-N-メチルベンゼンプロパン-1-アミン
  • rac-(R*)-3-フェニル-3-[4-(トリフルオロメチル)フェノキシ]-N-メチル-1-プロパンアミン
  • S-フルオキセチン
  • (3R)-N-メチル-3-フェニル-3-[4-(トリフルオロメチル)フェノキシ]プロパン-1-アミン
  • (R)-N-メチル-γ-[4-(トリフルオロメチル)フェノキシ]ベンゼンプロパンアミン
  • rac-(R*)-N-メチル-γ-[4-(トリフルオロメチル)フェノキシ]ベンゼンプロパン-1-アミン
  • R-フルオキセチン
  • (+)-フルオキセチン
  • セロトニン拮抗薬
  • 抗欝薬
Copyright 2017 © ChemicalBook. All rights reserved